2025-2030 年全球脊髓灰质炎联合疫苗市场预测（按疫苗类型、接种途径、技术、开发阶段和最终用户划分）

预计脊髓灰质炎疫苗市场规模到 2024 年将达到 26.3 亿美元，到 2025 年将达到 27.4 亿美元，到 2030 年将达到 33.4 亿美元，复合年增长率为 4.01%。

主要市场统计数据
基准年2024年	26.3亿美元
预计2025年	27.4亿美元
预测年份 2030	33.4亿美元
复合年增长率（%）	4.01%

小儿麻痹仍是全球疾病根除工作中最持久的目标之一，而联合疫苗製剂现已成为各种医疗环境中高效免疫策略的支柱。联合脊髓灰质炎疫苗将脊髓灰质炎脊髓灰质炎病毒抗原整合到一剂疫苗中，简化了复杂的供应链管理，减少了先前阻碍干预的低温运输株和物流限制。无论是在覆盖率高的常规免疫规划中，还是在快速应对疫情的宣传活动中，这些联合製剂都已证明能够在加快覆盖率的同时保持强大的安全性和有效性。因此，从国际卫生组织到国家卫生署的相关人员将联合脊髓灰质炎疫苗视为迈向无脊髓灰质炎世界的最后一搏的关键工具。

此外，联合疫苗研发的进展反映了尖端病毒学、先进佐剂科学和即时药物安全检测系统的整合。生物技术创新者与公共部门免疫计画之间的近期合作，催生了新型呈现抗原技术，该技术可优化免疫系统的启动，并减少副作用。这些进展与数位追踪平台相辅相成，增强了批次级可追溯性和低温运输完整性，从而提高了疫苗从生产到接种的可行性。因此，脊髓灰质炎联合疫苗如今在更广泛的多疾病免疫平台中占据战略地位，有助于加强全球卫生安全目标。

本执行摘要提炼了影响脊髓灰质炎疫苗组合市场格局的关键趋势、变化和外部压力。它深入分析了近期关税政策的累积影响，并揭示了按剂型、给药途径、技术、开发阶段和最终用户类型分類的细分动态，重点介绍了推动美洲、欧洲、中东和非洲以及亚太地区需求的区域差异。此外，它还提供了主要企业的策略分析、为产业决策者提供的可行建议，以及对这些研究结果所依据的严谨调查方法的概述。摘要最后提出了下一代免疫计画的策略建议。

揭示疫苗研发和分发的变革性转变，将重新定义全球脊髓灰质炎疫苗接种

在技​​术创新、法规不断演变以及公私合作日益加强的推动下，脊髓灰质炎联合疫苗领域近年来经历了一系列变革。疫苗研发人员正在利用平台技术实现抗原模组化，大幅缩短下一代製剂的临床推广时间。同时，全球卫生组织改进了审批途径，加快了紧急使用授权，以便在疫情爆发时快速部署联合剂量。这些监管改进统一了各主要市场的核准标准，为大规模生产和分销创造了更可预测的环境。

评估2025年美国关税对脊髓灰质炎疫苗製造供应链和全球成本结构的累积影响

2025年美国新关税的实施，为脊髓灰质炎疫苗供应链带来了复杂的挑战和策略考量。原料采购，尤其是生技药品级佐剂和管瓶，将面临更高的进口关税，进而对生产成本造成上行压力。因此，製造商正在重新评估筹资策略策略，重新协商供应商合同，并将生产转移到提供优惠贸易条件的国家。这导致供应链更加多元化，一些公司在东南亚和东欧建立了二级采购点，以对冲关税造成的成本波动。

重点細項分析，重点在于疫苗类型、给药途径、技术、开发阶段和最终用户的市场动态

分段分析揭示了不同疫苗类型的不同发展轨迹，由于抗原谱优化和低温运输要求简化，二价疫苗迅速成为常规免疫的预设选择。当流行病学调查中发现单一脊髓灰质炎病毒血清型时，单价疫苗透过以免疫学为重点的免疫接种，对于有针对性地控制疫情具有战略重要性。同时，三价疫苗仍然是广谱保护的基础，尤其是在优先考虑同时针对多种脊髓灰质炎株进行免疫接种的项目中。

重点介绍美洲、欧洲、中东和非洲地区以及亚太地区的市场驱动力和挑战

在美洲，完善的疫苗接种基础设施和稳定的监管途径造就了成熟的市场，其特点是高疫苗接种覆盖率。该地区的公私合作伙伴关係注重持续品质改进，并整合了先进的低温运输监控系统和数位记录平台，有助于确保都市区和偏远地区的疫苗接种率。

分析推动全球联合脊髓灰质炎疫苗领域发展的领先企业伙伴关係和创新

业内参与者采取了各种策略方针，以确保在脊髓灰质炎联合疫苗领域的主导。跨国製药公司透过瞄准和收购专业的生物技术开发公司，扩大了其产品组合。这种整合加速了获取新型抗原平台和重组表现系统的途径，这些平台和系统可作为下一代製剂的基础。同时，新兴生物科学公司已与成熟製造商建立了许可合作伙伴关係，以利用互补的规模化能力，推动创新候选疫苗进入后期临床试验和分销阶段。

为行业领导者提供可行的建议，以策略优先排序和投资脊髓灰质炎疫苗的开发和分发

为了最大限度地拓展脊髓灰质炎联合疫苗的开发和商业化机会，产业领导者应优先投资于能够增强抗原稳定性和免疫抗原性的先进佐剂和载体技术。透过将研发资源投入次单元和重组平台，企业可以提供差异化的安全性、耐热性和简化的低温运输要求。这种专注的努力将加快监管核准，并扩大先前因基础设施限製而覆盖范围有限的地区的疫苗可及性。

严谨的调查方法和资料收集框架的详细信息，为综合分析脊髓灰质炎疫苗市场动态奠定基础

本研究采用严谨的调查方法，将深入的二手资料收集与有针对性的一手资料研究结合，确保了研究的稳健性和有效性。二级资讯来源包括同行评审期刊、监管备案文件、技术白皮书和临床试验註册库，从而能够全面审查製剂技术、安全性概况和生产最佳实践。此外，我们也透过评估疫苗市场相关领域和免疫接种项目，进一步阐述了这些见解。

摘要关键发现并强调相关人员在製定脊髓灰质炎联合疫苗接种计划方面的策略要务

脊髓灰质炎联合疫苗领域正处于关键的十字路口，技术创新、供应链韧性和公平可及性是其共同面临的挑战。关键洞察包括：常规免疫计画中二价製剂的兴起、口服和注射给药途径的持续价值，以及正在重新定义耐热标准的次单元技术的兴起。此外，2025年的关税趋势正在推动供应链多元化和在地化生产，从而增强该产业的策略适应性。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章市场动态

• 开发新型佐剂技术以增强资源有限环境中的黏膜和体液免疫
• 加强监管协调，加速新版统一分次灭活脊髓灰质炎疫苗接种计画的核准
• 临床试验数据表明，含有脊髓灰质炎成分的六价疫苗在低收入国家具有非劣效免疫抗原性
• 透过与全球卫生组织和新兴生物技术公司的策略伙伴关係实现在地化製造
• 在联合疫苗中引入分剂量皮内注射IPV，以解决全球供不应求

第六章 市场洞察

• 波特五力分析
• PESTEL分析

第七章 2025年美国关税的累积影响

8.脊髓灰质炎联合疫苗市场（依疫苗类型）

• 二价疫苗
• 单价疫苗
• 三价疫苗

9.脊髓灰质炎联合疫苗市场（依接种途径）

• 注射
• 口服

10.脊髓灰质炎联合疫苗市场（依技术）

• 灭活脊髓灰质炎病毒疫苗
• 减毒活疫苗
• 次单位疫苗

11.脊髓灰质炎联合疫苗市场（依发展阶段）

• I期临床试验
• II期临床试验
• III期临床试验
• 临床前试验

12.脊髓灰质炎联合疫苗市场（依最终用户）

• 诊所
• 社区健康中心
• 医院
• 公共卫生实验室

13.美洲脊髓灰质炎联合疫苗市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 阿根廷

14. 欧洲、中东和非洲联合脊髓灰质炎疫苗市场

• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 阿拉伯聯合大公国
• 沙乌地阿拉伯
• 南非
• 丹麦
• 荷兰
• 卡达
• 芬兰
• 瑞典
• 奈及利亚
• 埃及
• 土耳其
• 以色列
• 挪威
• 波兰
• 瑞士

15. 亚太地区联合脊髓灰质炎疫苗市场

• 中国
• 印度
• 日本
• 澳洲
• 韩国
• 印尼
• 泰国
• 菲律宾
• 马来西亚
• 新加坡
• 越南
• 台湾

第十六章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Astellas Pharma Inc.
  • Bharat Immunologicals and Biologicals Corporation Limited
  • AstraZeneca PLC
  • Biological E. Limited
  • BioNTech SE
  • CSL Limited
  • Daiichi Sankyo Company, Limited.
  • GlaxoSmithKline PLC
  • Haffkine Bio-Pharmaceutical Corporation Ltd
  • Incepta Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Zydus Lifesciences Limited

第十七章 研究人工智慧

第十八章 研究统计

第十九章 研究联络人

第二十章 研究报导

第21章 附录

The Combined Polio Vaccine Market was valued at USD 2.63 billion in 2024 and is projected to grow to USD 2.74 billion in 2025, with a CAGR of 4.01%, reaching USD 3.34 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024]	USD 2.63 billion
Estimated Year [2025]	USD 2.74 billion
Forecast Year [2030]	USD 3.34 billion
CAGR (%)	4.01%

Poliomyelitis remains one of the most enduring targets in global disease eradication initiatives, with combined vaccine formulations now forming the backbone of efficient immunization strategies across diverse healthcare environments. By consolidating multiple poliovirus antigens within a single dose, combined polio vaccines have streamlined the complexities of supply chain management, reducing cold chain burdens and logistical constraints that once hindered outreach efforts. In both high-coverage routine immunization programs and rapid response campaigns to emergent outbreaks, these integrated formulations have demonstrated a capacity to accelerate coverage rates while maintaining robust safety and efficacy profiles. As a result, stakeholders from international health bodies to national ministries of health view combined polio vaccines as pivotal tools in the final push toward a polio-free world.

Moreover, the evolution of combined vaccine development reflects a convergence of cutting-edge virology, advanced adjuvant science, and real-time pharmacovigilance systems. Recent collaborations between biotech innovators and public sector immunization programs have produced novel antigen presentation technologies that optimize immune system priming with fewer side-effect trade-offs. These advancements have been complemented by digital tracking platforms that enhance batch-level traceability and cold chain integrity, ensuring higher rates of vaccine viability from production to point of administration. Consequently, combined polio vaccines now occupy a strategic position within broader multi-disease immunization platforms, reinforcing global health security objectives.

This executive summary distills the key trends, transformative shifts, and external pressures shaping the combined polio vaccine landscape. It delivers insights into the cumulative impact of recent tariff policies, unveils segmentation dynamics by formulation, administration route, technology, development stage, and end-user type, and highlights the regional nuances driving demand across the Americas, Europe, Middle East and Africa, and Asia-Pacific. In addition, it presents an analysis of leading company strategies, actionable recommendations for industry decision-makers, and an overview of the rigorous research methodology underpinning these findings. The summary concludes with strategic imperatives designed to inform the next generation of immunization initiatives.

Unveiling the Transformative Shifts in Vaccine Development and Distribution That Are Redefining the Polio Immunization Landscape Worldwide

The combined polio vaccine arena has undergone a series of transformative shifts over recent years, driven by technological innovation, evolving regulatory frameworks, and heightened collaboration across the public and private sectors. Vaccine developers have harnessed platform technologies that allow for modular antigen incorporation, significantly reducing time-to-clinic for next-generation formulations. Concurrently, global health agencies have refined licensure pathways to expedite emergency use authorizations, ensuring rapid deployment of combined doses during outbreak scenarios. These regulatory refinements have harmonized approval standards across key markets, fostering a more predictable environment for large-scale production and distribution.

In parallel, the advent of decentralized manufacturing models has disrupted traditional centralized production hubs. Strategic investments in regional fill-finish facilities now enable closer proximity to target populations, mitigating transportation risks and minimizing inventory aging. Digital thermosensitivity sensors and blockchain-enabled traceability systems have further increased supply chain resilience, enabling real-time visibility into vaccine integrity from factory floor to frontline clinics. As a result, immunization campaigns can pivot more nimbly in response to emergent epidemiological data, aligning inventory allocation with localized outbreak profiles and vaccination coverage gaps.

Furthermore, the integration of combined polio vaccines into broader multiplexed immunization schedules has catalyzed new public-private partnerships. Vaccine alliances are coordinating end-to-end distribution networks, co-funding community engagement initiatives, and deploying mobile immunization units equipped with cold chain autonomy. These collaborative models are breaking down historical silos between sector stakeholders, ensuring that combined polio vaccines are delivered with unprecedented speed and consistency to communities in need. Such shifts underscore the strategic imperative for manufacturers, policy makers, and global health organizations to align incentives around scale, access, and technological interoperability.

Assessing the Cumulative Impact of 2025 United States Tariffs on Combined Polio Vaccine Manufacturing Supply Chains and Cost Structures Globally

The implementation of new tariff measures by the United States in 2025 has introduced a complex set of challenges and strategic considerations for combined polio vaccine supply chains. Raw material sourcing, particularly of biologics-grade adjuvants and vials, has become subject to elevated import duties, exerting upward pressure on production expenditures. Consequently, manufacturers have been compelled to reevaluate procurement strategies, renegotiating supplier agreements or shifting production to jurisdictions offering preferential trade terms. This has prompted a wave of supply chain diversification, with several firms establishing secondary sourcing hubs in Southeast Asia and Eastern Europe to hedge against tariff-induced cost fluctuations.

At the same time, end-to-end manufacturing footprints are adapting to maintain both compliance and competitiveness. Vaccine producers have accelerated investments in onshore fill-finish capacity to partially neutralize tariff impact, deploying modular facilities that require lower capital expenditure and can scale in alignment with immunization campaign demands. While these localized operations offer a buffer against import duties, they also necessitate new regulatory submissions and quality assurance protocols, introducing additional layers of process complexity. Nevertheless, the strategic pivot toward more distributed manufacturing has enhanced supply chain adaptability and reduced lead times for critical orders.

Moreover, payer negotiations in both public and private healthcare channels are adjusting to accommodate the revised cost structures. Governments and procurement agencies are exploring volume-based agreements and risk-sharing frameworks to stabilize vaccine budgets. In parallel, global health financing bodies are recalibrating grant mechanisms to account for the residual tariff burden, ensuring immunization coverage targets remain within reach. Through these adaptive strategies, the sector is charting a path that balances fiscal sustainability with the imperative of maintaining uninterrupted access to life-saving combined polio vaccines.

Revealing Key Segmentation Insights That Illuminate Market Dynamics Across Vaccine Types Administration Routes Technologies Development Stages and End Users

Segmentation analysis reveals distinct trajectories across vaccine type categories, with bivalent formulations rapidly becoming the default choice for routine immunization due to their optimized antigenic profile and streamlined cold chain requirements. Monovalent variants retain strategic importance for targeted outbreak containment, offering heightened immunological focus when epidemiological surveillance identifies a single poliovirus serotype in circulation. Meanwhile, trivalent options continue to play a foundational role in broad-spectrum protection, particularly within programs prioritizing simultaneous immunity against multiple poliovirus strains.

Considering the route of administration, injectable combined polio vaccines remain predominant within hospital-based programs and clinical settings, where trained personnel administer doses under controlled conditions. Oral formulations, on the other hand, sustain their value in community outreach efforts, especially within remote or resource-constrained regions where ease of administration and minimal equipment requirements drive higher coverage metrics. Consequently, manufacturers are fine-tuning packaging formats and administration devices to meet the unique demands of each distribution channel.

From a technological standpoint, inactivated poliovirus vaccines maintain a leadership position owing to their established safety record and regulatory precedence. Live attenuated vaccines continue to serve crucial roles in outbreak response due to their robust mucosal immunity induction, while subunit vaccine candidates are emerging as next-generation solutions that promise enhanced thermostability and reduced reactogenicity. As these technological platforms advance through Phase I, Phase II, Phase III, and pre-clinical stages, clinical trial pipelines are diversifying, reflecting an industry impetus toward differentiated efficacy and safety profiles.

Finally, end-user segmentation illustrates varied adoption patterns: clinics and hospitals prioritize high-throughput, prefilled presentations for seamless integration into immunization schedules, whereas community health centers leverage lower-cost, bulk packaging to maximize resource allocation. Public health laboratories, tasked with batch release testing and cold chain monitoring, are instrumental in validating new product entries and ensuring compliance with stringent quality standards. Together, these segmentation insights illuminate the complex interplay of formulation, delivery method, technology, development progress, and end-user needs shaping the combined polio vaccine market.

Highlighting Critical Regional Insights That Uncover Growth Drivers and Challenges in the Americas Europe Middle East and Africa and Asia Pacific Markets

Regional dynamics underscore the divergent trajectories of combined polio vaccine adoption, beginning with the Americas, where well-established immunization infrastructures and stable regulatory pathways have fostered a mature market characterized by high coverage rates. In this region, public-private alliances emphasize continuous quality improvement, integrating advanced cold chain monitoring systems and digital record-keeping platforms to sustain robust vaccine uptake among both urban and remote populations.

Turning to Europe, the Middle East and Africa, collaborative networks have coalesced around shared public health objectives, leveraging pooled procurement mechanisms to secure favorable pricing and guarantee consistent supply. Regulatory harmonization initiatives among cooperating authorities have reduced approval lead times, while joint technical assistance programs support cold chain enhancements in areas with challenging logistics. As a result, combined polio vaccines are increasingly utilized within integrated immunization campaigns that address multiple vaccine-preventable diseases simultaneously.

In the Asia-Pacific region, the market is defined by rapid expansion of domestic manufacturing capacity and government-led immunization drives targeting hard-to-reach communities. Technology transfer agreements and local fill-finish partnerships have bolstered regional self-sufficiency, while tiered pricing frameworks ensure affordability across diverse income levels. Concurrent public awareness initiatives are enhancing caregiver education and demand generation, driving significant increases in both preventative routine coverage and reactive outbreak interventions. Collectively, these region-specific developments shape a multifaceted global landscape, requiring manufacturers and policy-makers to calibrate strategies that align with distinct regulatory, economic, and infrastructure considerations.

Analyzing Leading Corporate Strategies Partnerships and Innovations Driving Advancement in the Combined Polio Vaccine Sector Globally

Industry participants have adopted a range of strategic approaches to secure leadership in the combined polio vaccine domain, with multinational pharmaceutical firms expanding their portfolios through targeted acquisitions of specialized biotech developers. These integrations have accelerated access to novel antigen platforms and recombinant expression systems that underpin next-generation formulations. Concurrently, emerging bioscience companies are entering licensing partnerships with established manufacturers, leveraging complementary scale-up capabilities to bring innovative vaccine candidates through late-stage clinical trials and into distribution.

Strategic alliances with global health institutions have also emerged as key enablers of market penetration, as companies co-invest in infrastructure projects that strengthen cold chain resilience and enhance last-mile delivery. In parallel, technology innovators are collaborating on digital end-to-end traceability solutions that ensure product authenticity and real-time temperature monitoring, thereby mitigating spoilage risks and bolstering donor confidence.

Furthermore, a subset of manufacturers is differentiating through the development of combination therapies that integrate polio antigens with other childhood immunogens, streamlining immunization schedules and reducing the number of injections required over a child's first year. By pursuing regulatory designations that prioritize these multi-antigen presentations, companies aim to secure accelerated reviews and broaden their market reach. Across these varied strategic initiatives, a common thread emerges: the imperative to balance innovation speed with operational excellence, ensuring that combined polio vaccines remain accessible, reliable, and aligned with evolving public health priorities.

Providing Actionable Recommendations to Industry Leaders for Strategic Prioritization and Investment in Combined Polio Vaccine Development and Distribution

To capitalize on opportunities within the combined polio vaccine space, industry leaders should prioritize investment in advanced adjuvant and carrier technologies that enhance antigen stability and immunogenicity. By channeling research and development resources into subunit and recombinant platforms, companies can achieve differentiated safety profiles and thermal tolerances that simplify cold chain requirements. This focus will accelerate regulatory approvals and expand access in regions where infrastructure limitations have historically constrained coverage.

In addition, organizations must expand regional manufacturing footprints through modular, low-capex fill-finish facilities. Establishing localized production hubs not only mitigates tariff and logistics risks but also fosters stronger relationships with national health authorities. Accompanying these investments with targeted workforce training programs will ensure operational readiness and quality assurance compliance, positioning manufacturers to respond swiftly to outbreak demands.

Moreover, forging public-private partnerships that align procurement incentives with performance metrics can stabilize funding streams and reduce financial uncertainties. By negotiating volume-based contracts and outcome-linked payment models, companies and governments can distribute risk equitably while sustaining vaccine affordability. Simultaneously, embedding digital supply chain tracking systems will enhance transparency and facilitate dynamic allocation of inventory in response to real-time epidemiological data.

Finally, industry stakeholders should engage proactively in global regulatory harmonization forums to streamline clinical trial requirements and licensing processes. Shared technical guidelines and mutual recognition agreements will shorten time-to-market for novel combined polio formulations. Through these integrated strategies-spanning technological innovation, decentralized manufacturing, collaborative financing, and regulatory alignment-leaders can drive lasting improvements in polio immunization access and impact.

Detailing Rigorous Research Methodology and Data Collection Framework Underpinning the Comprehensive Analysis of Combined Polio Vaccines Market Dynamics

This research rested on a rigorous methodology that combined exhaustive secondary data collection with targeted primary consultations to ensure robustness and validity. Secondary sources included peer-reviewed journals, regulatory filings, technical white papers, and clinical trial registries, enabling a comprehensive review of formulation technologies, safety profiles, and manufacturing best practices. These insights were further contextualized through adjacencies in vaccine markets and immunization program evaluations.

Primary inputs were gathered via structured interviews with seasoned virologists, immunization program managers, supply chain experts, and regulatory affairs specialists. This qualitative engagement illuminated on-the-ground operational challenges and emerging opportunities, providing a nuanced understanding of both macro-level policies and micro-level execution realities. In addition, validation workshops with independent stakeholders served to cross-verify contentious data points and refine interpretation of tariff impacts and segmentation dynamics.

Analytical frameworks such as SWOT assessments, PESTLE analysis, and scenario planning underpinned the synthesis of findings, enabling a multi-dimensional exploration of competitive forces, geopolitical influences, and technological disruptions. Data triangulation techniques were applied at every stage, with iterative quality assurance processes ensuring that conflicting or anomalous inputs were reconciled. Ultimately, this blended methodology delivered a holistic perspective on combined polio vaccine market dynamics, equipping decision-makers with actionable intelligence grounded in empirical evidence and expert consensus.

Summarizing Core Findings and Emphasizing the Strategic Imperatives for Stakeholders in the Evolution of Combined Polio Vaccination Initiatives

The combined polio vaccine domain stands at a pivotal juncture, defined by concurrent imperatives for technological innovation, supply chain resilience, and equitable access. Core findings highlight the ascendancy of bivalent formulations in routine immunization programs, the sustained value of oral and injectable administration channels, and the emergence of subunit technologies poised to redefine thermostability standards. Moreover, the 2025 tariff landscape has catalyzed supply chain diversification and localized manufacturing investments, reinforcing the sector's strategic adaptability.

Regional nuances further underscore the importance of tailored approaches: the Americas' mature infrastructure and digital integration contrast with collaborative procurement models in Europe, the Middle East and Africa, and the rapid capacity-building initiatives underway in Asia-Pacific. Leading companies are responding with a spectrum of strategies, from cross-sector acquisitions to novel public-private partnership frameworks, all aimed at aligning innovation pipelines with global immunization objectives.

Strategic imperatives emerge from this analysis: fostering harmonized regulatory pathways, investing in modular production solutions, and embedding digital traceability within distribution networks. By operationalizing these recommendations, stakeholders can navigate policy volatility, enhance programmatic efficiency, and ultimately contribute to the enduring goal of global polio eradication. The convergence of technical advances and collaborative frameworks presents a unique window of opportunity to translate collective expertise into sustained public health impact.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Market Sizing & Forecasting

5. Market Dynamics

• 5.1. Development of novel adjuvant technologies to boost mucosal and humoral immunity in resource-limited settings
• 5.2. Regulatory harmonization efforts to accelerate approval of newly combined fractional inactivated polio vaccine schedules
• 5.3. Clinical trial data demonstrating noninferior immunogenicity of hexavalent vaccines including polio components in low-income countries
• 5.4. Strategic partnerships between global health organizations and emerging biotech firms to localize combined polio vaccine manufacturing
• 5.5. Implementation of fractional dose intradermal IPV in combination vaccines to address global supply shortages

6. Market Insights

• 6.1. Porter's Five Forces Analysis
• 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Combined Polio Vaccine Market, by Vaccine Type

• 8.1. Introduction
• 8.2. Bivalent Vaccine
• 8.3. Monovalent Vaccine
• 8.4. Trivalent Vaccine

9. Combined Polio Vaccine Market, by Route Of Administration

• 9.1. Introduction
• 9.2. Injectable Administration
• 9.3. Oral Administration

10. Combined Polio Vaccine Market, by Technology

• 10.1. Introduction
• 10.2. Inactivated Poliovirus Vaccines
• 10.3. Live Attenuated Vaccines
• 10.4. Subunit Vaccines

11. Combined Polio Vaccine Market, by Development Stage

• 11.1. Introduction
• 11.2. Phase I Clinical Trials
• 11.3. Phase II Clinical Trials
• 11.4. Phase III Clinical Trials
• 11.5. Pre-Clinical Trials

12. Combined Polio Vaccine Market, by End User

• 12.1. Introduction
• 12.2. Clinics
• 12.3. Community Health Centers
• 12.4. Hospitals
• 12.5. Public Health Laboratories

13. Americas Combined Polio Vaccine Market

• 13.1. Introduction
• 13.2. United States
• 13.3. Canada
• 13.4. Mexico
• 13.5. Brazil
• 13.6. Argentina

14. Europe, Middle East & Africa Combined Polio Vaccine Market

• 14.1. Introduction
• 14.2. United Kingdom
• 14.3. Germany
• 14.4. France
• 14.5. Russia
• 14.6. Italy
• 14.7. Spain
• 14.8. United Arab Emirates
• 14.9. Saudi Arabia
• 14.10. South Africa
• 14.11. Denmark
• 14.12. Netherlands
• 14.13. Qatar
• 14.14. Finland
• 14.15. Sweden
• 14.16. Nigeria
• 14.17. Egypt
• 14.18. Turkey
• 14.19. Israel
• 14.20. Norway
• 14.21. Poland
• 14.22. Switzerland

15. Asia-Pacific Combined Polio Vaccine Market

• 15.1. Introduction
• 15.2. China
• 15.3. India
• 15.4. Japan
• 15.5. Australia
• 15.6. South Korea
• 15.7. Indonesia
• 15.8. Thailand
• 15.9. Philippines
• 15.10. Malaysia
• 15.11. Singapore
• 15.12. Vietnam
• 15.13. Taiwan

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Astellas Pharma Inc.
  • 16.3.2. Bharat Immunologicals and Biologicals Corporation Limited
  • 16.3.3. AstraZeneca PLC
  • 16.3.4. Biological E. Limited
  • 16.3.5. BioNTech SE
  • 16.3.6. CSL Limited
  • 16.3.7. Daiichi Sankyo Company, Limited.
  • 16.3.8. GlaxoSmithKline PLC
  • 16.3.9. Haffkine Bio-Pharmaceutical Corporation Ltd
  • 16.3.10. Incepta Pharmaceuticals Ltd.
  • 16.3.11. Merck & Co., Inc.
  • 16.3.12. Mitsubishi Tanabe Pharma Corporation
  • 16.3.13. Panacea Biotec Ltd.
  • 16.3.14. Pfizer Inc.
  • 16.3.15. Sanofi S.A.
  • 16.3.16. Serum Institute of India Pvt. Ltd.
  • 16.3.17. Sinovac Biotech Ltd.
  • 16.3.18. Takeda Pharmaceutical Company Limited
  • 16.3.19. Zydus Lifesciences Limited

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

• FIGURE 1. COMBINED POLIO VACCINE MARKET RESEARCH PROCESS
• FIGURE 2. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 3. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 4. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
• FIGURE 6. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 8. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
• FIGURE 10. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2030 (%)
• FIGURE 12. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 14. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 16. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 18. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 21. ASIA-PACIFIC COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 22. ASIA-PACIFIC COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 23. COMBINED POLIO VACCINE MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 24. COMBINED POLIO VACCINE MARKET, FPNV POSITIONING MATRIX, 2024
• FIGURE 25. COMBINED POLIO VACCINE MARKET: RESEARCHAI
• FIGURE 26. COMBINED POLIO VACCINE MARKET: RESEARCHSTATISTICS
• FIGURE 27. COMBINED POLIO VACCINE MARKET: RESEARCHCONTACTS
• FIGURE 28. COMBINED POLIO VACCINE MARKET: RESEARCHARTICLES

LIST OF TABLES

• TABLE 1. COMBINED POLIO VACCINE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, 2025-2030 (USD MILLION)
• TABLE 5. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 7. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 9. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 11. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY BIVALENT VACCINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY BIVALENT VACCINE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 13. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY MONOVALENT VACCINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY MONOVALENT VACCINE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 15. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY TRIVALENT VACCINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY TRIVALENT VACCINE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 17. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 19. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY INJECTABLE ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY INJECTABLE ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
• TABLE 21. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
• TABLE 23. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 25. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY INACTIVATED POLIOVIRUS VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY INACTIVATED POLIOVIRUS VACCINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 27. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 29. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 31. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 33. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PHASE I CLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PHASE I CLINICAL TRIALS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 35. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PHASE II CLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PHASE II CLINICAL TRIALS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 37. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 39. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PRE-CLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PRE-CLINICAL TRIALS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 41. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 43. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 45. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 47. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 49. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 51. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 52. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 53. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 54. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 55. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 56. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 57. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 58. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 59. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 60. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 61. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 62. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 63. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 64. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 65. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 66. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 67. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 68. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 69. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 70. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 71. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 72. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 73. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
• TABLE 74. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
• TABLE 75. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 76. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 77. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 78. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 79. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 80. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 81. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 82. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 83. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 84. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 85. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 86. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 87. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 88. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 89. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 90. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 91. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 92. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 93. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 94. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 95. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 96. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 97. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 98. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 99. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 100. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 101. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 102. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 103. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 104. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 105. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 106. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 107. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 108. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 109. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 110. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 111. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 112. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 113. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 114. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 115. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 116. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 117. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 118. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 119. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 120. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 121. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 122. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 123. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 124. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 127. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 128. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 129. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 130. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 131. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 132. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 133. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 134. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 135. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 136. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 137. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 138. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 139. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 140. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 141. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 142. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 143. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 144. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 145. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 146. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 147. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 148. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 149. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 150. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 151. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 152. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 153. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 154. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 155. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 156. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 157. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 158. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 159. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 160. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 161. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 162. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 163. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 164. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 165. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 166. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 167. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 168. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 169. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 170. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 171. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 172. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 173. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 174. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 175. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 176. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 177. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 178. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 179. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 180. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 181. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 182. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 183. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 184. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 185. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 186. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 190. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 191. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 192. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 193. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 194. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 195. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 196. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 198. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 200. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 202. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 204. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 205. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 206. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 208. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 209. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 210. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 211. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 212. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 213. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 214. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 215. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 216. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 217. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 218. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 219. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 220. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 221. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 222. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 223. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 224. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 225. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 226. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 227. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 228. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 229. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 230. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 231. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 232. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 233. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 234. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 235. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 236. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 237. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 238. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 239. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 240. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 241. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 242. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 243. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 244. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 245. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 246. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 247. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 248. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 249. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 250. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 251. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 252. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 253. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 254. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 255. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 256. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 257. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 258. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 259. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 260. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 261. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 262. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 263. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 264. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 265. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 266. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 267. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 268. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 269. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 270. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 271. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 272. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 273. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 274. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 275. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 276. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 277. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 278. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 279. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 280. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 281. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 282. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 283. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 284. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 285. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 286. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 287. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 288. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 289. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 290. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 291. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 292. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 293. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 294. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 295. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 296. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 297. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 298. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 299. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 300. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 301. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 302. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 303. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 304. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 305. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 306. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 307. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 308. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 309. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 310. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 311. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 312. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 313. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 314. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 315. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 316. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 317. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 318. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
• TABLE 319. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 320. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 321. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 322. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 323. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 324. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
• TABLE 325. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 326. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 327. SWITZERLAND COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILL